Skip to content

PEAK PHARMACEUTICALS, INC.: 10-Q/A filed 2011-09-08

What PEAK PHARMACEUTICALS, INC. reported in its quarterly report amendment filed 2011-09-08 (fiscal Q3 2011): 17 published measures, 60 facts as tagged in accession 0001165527-11-000846.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2011-09-08
Fiscal period
fiscal Q3 2011
Accession
0001165527-11-000846 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PEAK PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-06-3010,248USD
At 2010-09-3019,470USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-06-3061,000USD
At 2010-09-3010,554USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-06-3094USD
At 2010-09-3010,916USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-06-308,480USD
At 2010-09-3017,470USD
At 2010-06-3021,040USD
At 2009-09-3010,744USD
At 2007-12-160USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2010-10-01 to 2011-06-30-8,822USD273
2007-12-17 to 2011-06-30-60,906USD1292
2009-10-01 to 2010-06-30-15,174USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2010-10-01 to 2011-06-30-8,990USD273
2007-12-17 to 2011-06-30-52,520USD1292
2009-10-01 to 2010-06-30-14,704USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-04-01 to 2011-06-300USD91
2010-10-01 to 2011-06-300USD273
2007-12-17 to 2011-06-300USD1292
2010-04-01 to 2010-06-300USD91
2009-10-01 to 2010-06-300USD273

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2011-04-01 to 2011-06-304,410,000shares91
2010-10-01 to 2011-06-304,410,000shares273
2010-04-01 to 2010-06-304,410,000shares91
2009-10-01 to 2010-06-304,363,433shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2011-04-01 to 2011-06-300USD/shares91
2010-10-01 to 2011-06-300USD/shares273
2010-04-01 to 2010-06-300USD/shares91
2009-10-01 to 2010-06-300USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2011-04-01 to 2011-06-300USD91
2010-10-01 to 2011-06-300USD273
2007-12-17 to 2011-06-300USD1292
2010-04-01 to 2010-06-300USD91
2009-10-01 to 2010-06-300USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-06-304,410,000shares
At 2010-09-304,410,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-06-3056,590USD
At 2010-09-3056,590USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-2,530USD91
2010-10-01 to 2011-06-30-8,822USD273
2007-12-17 to 2011-06-30-60,906USD1292
2010-04-01 to 2010-06-30-2,774USD91
2009-10-01 to 2010-06-30-15,174USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-2,530USD91
2010-10-01 to 2011-06-30-8,822USD273
2007-12-17 to 2011-06-30-60,906USD1292
2010-04-01 to 2010-06-30-2,774USD91
2009-10-01 to 2010-06-30-15,174USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-04-01 to 2011-06-302,530USD91
2010-10-01 to 2011-06-308,822USD273
2007-12-17 to 2011-06-3060,906USD1292
2010-04-01 to 2010-06-302,774USD91
2009-10-01 to 2010-06-3015,174USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2010-10-01 to 2011-06-300USD273
2007-12-17 to 2011-06-3061,000USD1292
2009-10-01 to 2010-06-300USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2010-10-01 to 2011-06-30-400USD273
2007-12-17 to 2011-06-3010,154USD1292
2009-10-01 to 2010-06-302,350USD273

Inspect the source

Entity
PEAK PHARMACEUTICALS, INC. / CIK 0001452804
Captured
2026-09-20T09:05:40.595Z
SEC response SHA-256
3fd5eb06bfdebffa42021b094c4c379c1efd3c7143204265bf035090db070211

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001452804.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))